Uncharactered LOC400863: A Potential Drug Target and Biomarker

Target Name: Uncharactered LOC400863

NCBI ID: G400863

Uncharactered LOC400863

Other Name(s): Uncharacterized protein LOC400863 | LOC400863

Uncharactered LOC400863: A Potential Drug Target and Biomarker

Uncharactered LOC400863 (LOC400863) is a protein that has been identified as a potential drug target and biomarker. It is a member of the LOC40086 family, which is known for its role in various cellular processes, including cell signaling, DNA replication, and apoptosis. LOC400863 has been shown to play a crucial role in the regulation of cell proliferation and has been associated with various diseases, including cancer.

The Protein Structure and Function

LOC400863 is a 21-kDa protein that is expressed in various tissues, including liver, lung, and breast cells. It has a molecular weight of 41.9 kDa and a calculated pI of 6.3. LOC400863 is a monoclonal antibody, which means that it is produced by a single cell and has a single antibody molecule.

The LOC400863 protein has a unique structure that is composed of a single transmembrane domain and a cytoplasmic tail. The transmembrane domain is responsible for the protein's membrane association and is involved in the regulation of cell signaling pathways. The cytoplasmic tail is involved in the protein's stability and interacts with various cellular structures, including the endoplasmic reticulum and the nuclear envelope.

LOC400863 has been shown to play a role in various cellular processes, including cell signaling, DNA replication, and apoptosis. For example, studies have shown that LOC400863 is involved in the regulation of cell proliferation, cell cycle progression, and the apoptosis process. Additionally, LOC400863 has been shown to interact with various proteins, including T-cell receptor (TCR),PD-L1, and NF-kappa-B.

The Potential Drug Target

LOC400863 has been identified as a potential drug target due to its involvement in various cellular processes that are associated with cancer. For example, studies have shown that LOC400863 is involved in the regulation of cell proliferation and has been associated with the development of various types of cancer, including breast, lung, and liver cancer. Additionally, LOC400863 has been shown to interact with various proteins that are known to be involved in cancer progression, including T-cell receptor (TCR),PD-L1, and NF-kappa-B.

The Biomarker Potential

LOC400863 has also been identified as a potential biomarker for various types of cancer. Studies have shown that LOC400863 is expressed in various types of cancer and has been used as a biomarker for cancer diagnosis and treatment. For example, studies have shown that LOC400863 can be used as a biomarker for breast cancer and that it can be used to predict the outcome of chemotherapy in patients with breast cancer.

Conclusion

Uncharactered LOC400863 is a protein that has been identified as a potential drug target and biomarker. Its unique structure and function, as well as its involvement in various cellular processes that are associated with cancer, make it an attractive target for drug development. Further studies are needed to fully understand the potential of LOC400863 as a drug target and biomarker.

Protein Name: Uncharactered LOC400863

The "Uncharactered LOC400863 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Uncharactered LOC400863 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets